Together these results demonstrate that a subset of non-neutralising anti-RBD mAbs, or neutralising mAbs at sub-neutralising concentrations, can expand the tropism of SARS-CoV-2 to monocytic cells, frequently at infection levels comparable to those seen in typical ACE2-mediated infection of permissive cells. This evidence concerns the gene ACE2 and infection.